3Harris NL,Jaffe ES,Stein H,et al.A revised European-American classification of lymphoid neoplasma:aproposalfrom the international lymphoma study group[J].Blood,1994,84(2):1361.
2[21]Yamaguchi M, Kita, K, Miwa H. et al. Frequent expression of P- glycoprotein / MDR1 by nasal T- cell lymphoma cells.Cancer, 1995, 76:2351
3[23]Yong W, Zheng W, Zhang Y, et al. L- asparaginasebased regimen in the treatment of refractory midline nasal/nasal - type T/NK- cell lymphoma. Int J Hematol, 2003, 78: 163
4[24]Nagafuji K, Fujisaki t, Arima F. et al. L- asparagine induced durable remission of relapsed nasal NK/T - cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol, 2001, 74:447
5[25]Sherf U, Ross DT, Waltthom M, et al. A gene expression data base for the molecular pharmacology of cancer. Nat Genet,2000, 24 (3) :236
6[26]Kitoh T, Suzuki T, Nagafuji K, et al. Identification of Lasparaginase sensitivity nasal natural killer/natural killer- like T- cell lymphoma: Usefulness of mmunostaining result for asparagine synthetase in lymphoma cells. Ketsueki - SchuyouKa, 2003, 46:108
7[27]Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplantation, 1997, 19 (1):91
8[28]Takenaka K, Shinagawa K, Maeda Y, et al. High- dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal- type CD56+ natural killer cell lymphomas. LeukLymphoma, 2001, 42 (6) :1297
9[1]Harris NL, Jaffe ES, Stein H, et al. A revised EuropeanAmerican classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood, 1994, 84:1361
10[2]Jaffe ES. Introduction to the WHO classification. Am J Surg Pathol, 1997, 21: 114
